Stockreport

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]

Bicara Therapeutics Inc.  (BCAX) 
PDF Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients expected at ESM [Read more]